Daphne Koller, insitro CEO (Stefan Wermuth/Bloomberg via Getty Images)
October 9, 2024 07:00 AM EDTUpdated 10:23 AM
Deals
R&D
AI

AI biotech in­sitro part­ners with Lil­ly on meta­bol­ic dis­ease drugs

Ryan Cross

Senior Science Correspondent

If all goes ac­cord­ing to plan, in­sitro could fi­nal­ly start test­ing its first drug in clin­i­cal tri­als in 2026, eight years af­ter Daphne Koller found­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

David Bak­er, Demis Has­s­abis and John Jumper win chem­istry No­bel for com­pu­ta­tion­al pro­tein pre­dic­tion and de­sign

Kevin Tang's Con­cen­tra swoops in on an­oth­er strug­gling biotech, of­fer­ing to buy Kezar

Pure­spring nabs $105M to take gene ther­a­py in­to the clin­ic as IgAN field ma­tures

Base­camp rais­es $60M to trav­el the globe and fill AI da­ta gaps, signs deal with David Liu

‘Just the be­gin­ning’: No­bel Prizes show the AI era has ar­rived in biotech

No­bel Prize win­ner Demis Has­s­abis talks about his vi­sion for Iso­mor­phic and AI’s fu­ture in biotech

A service from the Financial Times